English
简体中文
Total: £ 56.28
Published Date: 2025-01-13 | Pages: 97 | Tables: 88 | Pharma & Healthcare
The global market for Eosinophilic Esophagitis Drug was valued at US$ 144 million in the year 2024 and is projected to reach a revised size of US$ 209 million by 2031, growing at a CAGR of 5.5% during the forecast period.
Eosinophilic esophagitis (EoE, also spelled eosinophilic oesophagitis), also known as allergic oesophagitis, is an allergic inflammatory condition of the esophagus that involves eosinophils, a type of white blood cell. Symptoms are swallowing difficulty, food impaction, vomiting, and heartburn.
Eosinophilic esophagitis was first described in children but also occurs in adults. The condition is not well understood, but food allergy may play a significant role. The treatment may consist of removal of known or suspected triggers and medication to suppress the immune response.
This report studies the eosinophilic esophagitis drug market.
AstraZeneca, GSK and Bayer are the leading producers of eosinophilic esophagitis drug, which together account for about 80% of the market.
North America is the leading region, accounting for more than 30% of the market, followed by Europe at nearly 30%.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Eosinophilic Esophagitis Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Eosinophilic Esophagitis Drug.
The Eosinophilic Esophagitis Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Eosinophilic Esophagitis Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Eosinophilic Esophagitis Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
AstraZeneca
GSK
Bayer
Adare Pharmaceuticals
DBV Technologies
Dr. Falk Pharma
Quorum Innovations
Takeda
Calypso
Celgene
Regeneron
Segment by Type
Budesonide
Fluticasone
Others
Segment by Application
Hospitals
Clinics
Drugstore
Consumption by Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
U.A.E
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Eosinophilic Esophagitis Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Eosinophilic Esophagitis Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Eosinophilic Esophagitis Drug Market Overview
1.1 Product Definition
1.2 Eosinophilic Esophagitis Drug by Type
1.2.1 Global Eosinophilic Esophagitis Drug Market Value Comparison by Type (2024 VS 2031)
1.2.2 Budesonide
1.2.3 Fluticasone
1.2.4 Others
1.3 Eosinophilic Esophagitis Drug by Application
1.3.1 Global Eosinophilic Esophagitis Drug Market Value by Application (2024 VS 2031)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Drugstore
1.4 Global Eosinophilic Esophagitis Drug Market Size Estimates and Forecasts
1.4.1 Global Eosinophilic Esophagitis Drug Revenue 2020-2031
1.4.2 Global Eosinophilic Esophagitis Drug Sales 2020-2031
1.4.3 Global Eosinophilic Esophagitis Drug Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Eosinophilic Esophagitis Drug Market Competition by Manufacturers
2.1 Global Eosinophilic Esophagitis Drug Sales Market Share by Manufacturers (2020-2025)
2.2 Global Eosinophilic Esophagitis Drug Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Eosinophilic Esophagitis Drug Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Eosinophilic Esophagitis Drug, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Eosinophilic Esophagitis Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Eosinophilic Esophagitis Drug, Product Type & Application
2.7 Global Key Manufacturers of Eosinophilic Esophagitis Drug, Date of Enter into This Industry
2.8 Global Eosinophilic Esophagitis Drug Market Competitive Situation and Trends
2.8.1 Global Eosinophilic Esophagitis Drug Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Eosinophilic Esophagitis Drug Players Market Share by Revenue
2.8.3 Global Eosinophilic Esophagitis Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Eosinophilic Esophagitis Drug Market Scenario by Region
3.1 Global Eosinophilic Esophagitis Drug Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Eosinophilic Esophagitis Drug Sales by Region: 2020-2031
3.2.1 Global Eosinophilic Esophagitis Drug Sales by Region: 2020-2025
3.2.2 Global Eosinophilic Esophagitis Drug Sales by Region: 2026-2031
3.3 Global Eosinophilic Esophagitis Drug Revenue by Region: 2020-2031
3.3.1 Global Eosinophilic Esophagitis Drug Revenue by Region: 2020-2025
3.3.2 Global Eosinophilic Esophagitis Drug Revenue by Region: 2026-2031
3.4 North America Eosinophilic Esophagitis Drug Market Facts & Figures by Country
3.4.1 North America Eosinophilic Esophagitis Drug Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Eosinophilic Esophagitis Drug Sales by Country (2020-2031)
3.4.3 North America Eosinophilic Esophagitis Drug Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Eosinophilic Esophagitis Drug Market Facts & Figures by Country
3.5.1 Europe Eosinophilic Esophagitis Drug Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Eosinophilic Esophagitis Drug Sales by Country (2020-2031)
3.5.3 Europe Eosinophilic Esophagitis Drug Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Eosinophilic Esophagitis Drug Market Facts & Figures by Region
3.6.1 Asia Pacific Eosinophilic Esophagitis Drug Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Eosinophilic Esophagitis Drug Sales by Region (2020-2031)
3.6.3 Asia Pacific Eosinophilic Esophagitis Drug Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Eosinophilic Esophagitis Drug Market Facts & Figures by Country
3.7.1 Latin America Eosinophilic Esophagitis Drug Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Eosinophilic Esophagitis Drug Sales by Country (2020-2031)
3.7.3 Latin America Eosinophilic Esophagitis Drug Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Eosinophilic Esophagitis Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Eosinophilic Esophagitis Drug Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Eosinophilic Esophagitis Drug Sales by Country (2020-2031)
3.8.3 Middle East and Africa Eosinophilic Esophagitis Drug Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Eosinophilic Esophagitis Drug Sales by Type (2020-2031)
4.1.1 Global Eosinophilic Esophagitis Drug Sales by Type (2020-2025)
4.1.2 Global Eosinophilic Esophagitis Drug Sales by Type (2026-2031)
4.1.3 Global Eosinophilic Esophagitis Drug Sales Market Share by Type (2020-2031)
4.2 Global Eosinophilic Esophagitis Drug Revenue by Type (2020-2031)
4.2.1 Global Eosinophilic Esophagitis Drug Revenue by Type (2020-2025)
4.2.2 Global Eosinophilic Esophagitis Drug Revenue by Type (2026-2031)
4.2.3 Global Eosinophilic Esophagitis Drug Revenue Market Share by Type (2020-2031)
4.3 Global Eosinophilic Esophagitis Drug Price by Type (2020-2031)
5 Segment by Application
5.1 Global Eosinophilic Esophagitis Drug Sales by Application (2020-2031)
5.1.1 Global Eosinophilic Esophagitis Drug Sales by Application (2020-2025)
5.1.2 Global Eosinophilic Esophagitis Drug Sales by Application (2026-2031)
5.1.3 Global Eosinophilic Esophagitis Drug Sales Market Share by Application (2020-2031)
5.2 Global Eosinophilic Esophagitis Drug Revenue by Application (2020-2031)
5.2.1 Global Eosinophilic Esophagitis Drug Revenue by Application (2020-2025)
5.2.2 Global Eosinophilic Esophagitis Drug Revenue by Application (2026-2031)
5.2.3 Global Eosinophilic Esophagitis Drug Revenue Market Share by Application (2020-2031)
5.3 Global Eosinophilic Esophagitis Drug Price by Application (2020-2031)
6 Key Companies Profiled
6.1 AstraZeneca
6.1.1 AstraZeneca Company Information
6.1.2 AstraZeneca Description and Business Overview
6.1.3 AstraZeneca Eosinophilic Esophagitis Drug Sales, Revenue and Gross Margin (2020-2025)
6.1.4 AstraZeneca Eosinophilic Esophagitis Drug Product Portfolio
6.1.5 AstraZeneca Recent Developments/Updates
6.2 GSK
6.2.1 GSK Company Information
6.2.2 GSK Description and Business Overview
6.2.3 GSK Eosinophilic Esophagitis Drug Sales, Revenue and Gross Margin (2020-2025)
6.2.4 GSK Eosinophilic Esophagitis Drug Product Portfolio
6.2.5 GSK Recent Developments/Updates
6.3 Bayer
6.3.1 Bayer Company Information
6.3.2 Bayer Description and Business Overview
6.3.3 Bayer Eosinophilic Esophagitis Drug Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Bayer Eosinophilic Esophagitis Drug Product Portfolio
6.3.5 Bayer Recent Developments/Updates
6.4 Adare Pharmaceuticals
6.4.1 Adare Pharmaceuticals Company Information
6.4.2 Adare Pharmaceuticals Description and Business Overview
6.4.3 Adare Pharmaceuticals Eosinophilic Esophagitis Drug Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Adare Pharmaceuticals Eosinophilic Esophagitis Drug Product Portfolio
6.4.5 Adare Pharmaceuticals Recent Developments/Updates
6.5 DBV Technologies
6.5.1 DBV Technologies Company Information
6.5.2 DBV Technologies Description and Business Overview
6.5.3 DBV Technologies Eosinophilic Esophagitis Drug Sales, Revenue and Gross Margin (2020-2025)
6.5.4 DBV Technologies Eosinophilic Esophagitis Drug Product Portfolio
6.5.5 DBV Technologies Recent Developments/Updates
6.6 Dr. Falk Pharma
6.6.1 Dr. Falk Pharma Company Information
6.6.2 Dr. Falk Pharma Description and Business Overview
6.6.3 Dr. Falk Pharma Eosinophilic Esophagitis Drug Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Dr. Falk Pharma Eosinophilic Esophagitis Drug Product Portfolio
6.6.5 Dr. Falk Pharma Recent Developments/Updates
6.7 Quorum Innovations
6.7.1 Quorum Innovations Company Information
6.7.2 Quorum Innovations Description and Business Overview
6.7.3 Quorum Innovations Eosinophilic Esophagitis Drug Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Quorum Innovations Eosinophilic Esophagitis Drug Product Portfolio
6.7.5 Quorum Innovations Recent Developments/Updates
6.8 Takeda
6.8.1 Takeda Company Information
6.8.2 Takeda Description and Business Overview
6.8.3 Takeda Eosinophilic Esophagitis Drug Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Takeda Eosinophilic Esophagitis Drug Product Portfolio
6.8.5 Takeda Recent Developments/Updates
6.9 Calypso
6.9.1 Calypso Company Information
6.9.2 Calypso Description and Business Overview
6.9.3 Calypso Eosinophilic Esophagitis Drug Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Calypso Eosinophilic Esophagitis Drug Product Portfolio
6.9.5 Calypso Recent Developments/Updates
6.10 Celgene
6.10.1 Celgene Company Information
6.10.2 Celgene Description and Business Overview
6.10.3 Celgene Eosinophilic Esophagitis Drug Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Celgene Eosinophilic Esophagitis Drug Product Portfolio
6.10.5 Celgene Recent Developments/Updates
6.11 Regeneron
6.11.1 Regeneron Company Information
6.11.2 Regeneron Description and Business Overview
6.11.3 Regeneron Eosinophilic Esophagitis Drug Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Regeneron Eosinophilic Esophagitis Drug Product Portfolio
6.11.5 Regeneron Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Eosinophilic Esophagitis Drug Industry Chain Analysis
7.2 Eosinophilic Esophagitis Drug Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Eosinophilic Esophagitis Drug Production Mode & Process Analysis
7.4 Eosinophilic Esophagitis Drug Sales and Marketing
7.4.1 Eosinophilic Esophagitis Drug Sales Channels
7.4.2 Eosinophilic Esophagitis Drug Distributors
7.5 Eosinophilic Esophagitis Drug Customer Analysis
8 Eosinophilic Esophagitis Drug Market Dynamics
8.1 Eosinophilic Esophagitis Drug Industry Trends
8.2 Eosinophilic Esophagitis Drug Market Drivers
8.3 Eosinophilic Esophagitis Drug Market Challenges
8.4 Eosinophilic Esophagitis Drug Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Eosinophilic Esophagitis Drug Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Eosinophilic Esophagitis Drug Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Eosinophilic Esophagitis Drug Market Competitive Situation by Manufacturers in 2024
Table 4. Global Eosinophilic Esophagitis Drug Sales (K Units) of Key Manufacturers (2020-2025)
Table 5. Global Eosinophilic Esophagitis Drug Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Eosinophilic Esophagitis Drug Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Eosinophilic Esophagitis Drug Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Eosinophilic Esophagitis Drug Average Price (USD/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Eosinophilic Esophagitis Drug, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Eosinophilic Esophagitis Drug, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Eosinophilic Esophagitis Drug, Product Type & Application
Table 12. Global Key Manufacturers of Eosinophilic Esophagitis Drug, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Eosinophilic Esophagitis Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Eosinophilic Esophagitis Drug as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Eosinophilic Esophagitis Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Eosinophilic Esophagitis Drug Sales by Region (2020-2025) & (K Units)
Table 18. Global Eosinophilic Esophagitis Drug Sales Market Share by Region (2020-2025)
Table 19. Global Eosinophilic Esophagitis Drug Sales by Region (2026-2031) & (K Units)
Table 20. Global Eosinophilic Esophagitis Drug Sales Market Share by Region (2026-2031)
Table 21. Global Eosinophilic Esophagitis Drug Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Eosinophilic Esophagitis Drug Revenue Market Share by Region (2020-2025)
Table 23. Global Eosinophilic Esophagitis Drug Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Eosinophilic Esophagitis Drug Revenue Market Share by Region (2026-2031)
Table 25. North America Eosinophilic Esophagitis Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Eosinophilic Esophagitis Drug Sales by Country (2020-2025) & (K Units)
Table 27. North America Eosinophilic Esophagitis Drug Sales by Country (2026-2031) & (K Units)
Table 28. North America Eosinophilic Esophagitis Drug Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Eosinophilic Esophagitis Drug Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Eosinophilic Esophagitis Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Eosinophilic Esophagitis Drug Sales by Country (2020-2025) & (K Units)
Table 32. Europe Eosinophilic Esophagitis Drug Sales by Country (2026-2031) & (K Units)
Table 33. Europe Eosinophilic Esophagitis Drug Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Eosinophilic Esophagitis Drug Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Eosinophilic Esophagitis Drug Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Eosinophilic Esophagitis Drug Sales by Region (2020-2025) & (K Units)
Table 37. Asia Pacific Eosinophilic Esophagitis Drug Sales by Region (2026-2031) & (K Units)
Table 38. Asia Pacific Eosinophilic Esophagitis Drug Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Eosinophilic Esophagitis Drug Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Eosinophilic Esophagitis Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Eosinophilic Esophagitis Drug Sales by Country (2020-2025) & (K Units)
Table 42. Latin America Eosinophilic Esophagitis Drug Sales by Country (2026-2031) & (K Units)
Table 43. Latin America Eosinophilic Esophagitis Drug Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Eosinophilic Esophagitis Drug Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Eosinophilic Esophagitis Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Eosinophilic Esophagitis Drug Sales by Country (2020-2025) & (K Units)
Table 47. Middle East and Africa Eosinophilic Esophagitis Drug Sales by Country (2026-2031) & (K Units)
Table 48. Middle East and Africa Eosinophilic Esophagitis Drug Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Eosinophilic Esophagitis Drug Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Eosinophilic Esophagitis Drug Sales (K Units) by Type (2020-2025)
Table 51. Global Eosinophilic Esophagitis Drug Sales (K Units) by Type (2026-2031)
Table 52. Global Eosinophilic Esophagitis Drug Sales Market Share by Type (2020-2025)
Table 53. Global Eosinophilic Esophagitis Drug Sales Market Share by Type (2026-2031)
Table 54. Global Eosinophilic Esophagitis Drug Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Eosinophilic Esophagitis Drug Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Eosinophilic Esophagitis Drug Revenue Market Share by Type (2020-2025)
Table 57. Global Eosinophilic Esophagitis Drug Revenue Market Share by Type (2026-2031)
Table 58. Global Eosinophilic Esophagitis Drug Price (USD/Unit) by Type (2020-2025)
Table 59. Global Eosinophilic Esophagitis Drug Price (USD/Unit) by Type (2026-2031)
Table 60. Global Eosinophilic Esophagitis Drug Sales (K Units) by Application (2020-2025)
Table 61. Global Eosinophilic Esophagitis Drug Sales (K Units) by Application (2026-2031)
Table 62. Global Eosinophilic Esophagitis Drug Sales Market Share by Application (2020-2025)
Table 63. Global Eosinophilic Esophagitis Drug Sales Market Share by Application (2026-2031)
Table 64. Global Eosinophilic Esophagitis Drug Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Eosinophilic Esophagitis Drug Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Eosinophilic Esophagitis Drug Revenue Market Share by Application (2020-2025)
Table 67. Global Eosinophilic Esophagitis Drug Revenue Market Share by Application (2026-2031)
Table 68. Global Eosinophilic Esophagitis Drug Price (USD/Unit) by Application (2020-2025)
Table 69. Global Eosinophilic Esophagitis Drug Price (USD/Unit) by Application (2026-2031)
Table 70. AstraZeneca Company Information
Table 71. AstraZeneca Description and Business Overview
Table 72. AstraZeneca Eosinophilic Esophagitis Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 73. AstraZeneca Eosinophilic Esophagitis Drug Product
Table 74. AstraZeneca Recent Developments/Updates
Table 75. GSK Company Information
Table 76. GSK Description and Business Overview
Table 77. GSK Eosinophilic Esophagitis Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 78. GSK Eosinophilic Esophagitis Drug Product
Table 79. GSK Recent Developments/Updates
Table 80. Bayer Company Information
Table 81. Bayer Description and Business Overview
Table 82. Bayer Eosinophilic Esophagitis Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 83. Bayer Eosinophilic Esophagitis Drug Product
Table 84. Bayer Recent Developments/Updates
Table 85. Adare Pharmaceuticals Company Information
Table 86. Adare Pharmaceuticals Description and Business Overview
Table 87. Adare Pharmaceuticals Eosinophilic Esophagitis Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 88. Adare Pharmaceuticals Eosinophilic Esophagitis Drug Product
Table 89. Adare Pharmaceuticals Recent Developments/Updates
Table 90. DBV Technologies Company Information
Table 91. DBV Technologies Description and Business Overview
Table 92. DBV Technologies Eosinophilic Esophagitis Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 93. DBV Technologies Eosinophilic Esophagitis Drug Product
Table 94. DBV Technologies Recent Developments/Updates
Table 95. Dr. Falk Pharma Company Information
Table 96. Dr. Falk Pharma Description and Business Overview
Table 97. Dr. Falk Pharma Eosinophilic Esophagitis Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 98. Dr. Falk Pharma Eosinophilic Esophagitis Drug Product
Table 99. Dr. Falk Pharma Recent Developments/Updates
Table 100. Quorum Innovations Company Information
Table 101. Quorum Innovations Description and Business Overview
Table 102. Quorum Innovations Eosinophilic Esophagitis Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 103. Quorum Innovations Eosinophilic Esophagitis Drug Product
Table 104. Quorum Innovations Recent Developments/Updates
Table 105. Takeda Company Information
Table 106. Takeda Description and Business Overview
Table 107. Takeda Eosinophilic Esophagitis Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 108. Takeda Eosinophilic Esophagitis Drug Product
Table 109. Takeda Recent Developments/Updates
Table 110. Calypso Company Information
Table 111. Calypso Description and Business Overview
Table 112. Calypso Eosinophilic Esophagitis Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 113. Calypso Eosinophilic Esophagitis Drug Product
Table 114. Calypso Recent Developments/Updates
Table 115. Celgene Company Information
Table 116. Celgene Description and Business Overview
Table 117. Celgene Eosinophilic Esophagitis Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 118. Celgene Eosinophilic Esophagitis Drug Product
Table 119. Celgene Recent Developments/Updates
Table 120. Regeneron Company Information
Table 121. Regeneron Description and Business Overview
Table 122. Regeneron Eosinophilic Esophagitis Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 123. Regeneron Eosinophilic Esophagitis Drug Product
Table 124. Regeneron Recent Developments/Updates
Table 125. Key Raw Materials Lists
Table 126. Raw Materials Key Suppliers Lists
Table 127. Eosinophilic Esophagitis Drug Distributors List
Table 128. Eosinophilic Esophagitis Drug Customers List
Table 129. Eosinophilic Esophagitis Drug Market Trends
Table 130. Eosinophilic Esophagitis Drug Market Drivers
Table 131. Eosinophilic Esophagitis Drug Market Challenges
Table 132. Eosinophilic Esophagitis Drug Market Restraints
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources
Table 136. Authors List of This Report
List of Figures
Figure 1. Product Picture of Eosinophilic Esophagitis Drug
Figure 2. Global Eosinophilic Esophagitis Drug Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Eosinophilic Esophagitis Drug Market Share by Type: 2024 & 2031
Figure 4. Budesonide Product Picture
Figure 5. Fluticasone Product Picture
Figure 6. Others Product Picture
Figure 7. Global Eosinophilic Esophagitis Drug Market Value by Application (2020-2031) & (US$ Million)
Figure 8. Global Eosinophilic Esophagitis Drug Market Share by Application: 2024 & 2031
Figure 9. Hospitals
Figure 10. Clinics
Figure 11. Drugstore
Figure 12. Global Eosinophilic Esophagitis Drug Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Eosinophilic Esophagitis Drug Market Size (2020-2031) & (US$ Million)
Figure 14. Global Eosinophilic Esophagitis Drug Sales (2020-2031) & (K Units)
Figure 15. Global Eosinophilic Esophagitis Drug Average Price (USD/Unit) & (2020-2031)
Figure 16. Eosinophilic Esophagitis Drug Report Years Considered
Figure 17. Eosinophilic Esophagitis Drug Sales Share by Manufacturers in 2024
Figure 18. Global Eosinophilic Esophagitis Drug Revenue Share by Manufacturers in 2024
Figure 19. Global 5 and 10 Largest Eosinophilic Esophagitis Drug Players: Market Share by Revenue in Eosinophilic Esophagitis Drug in 2024
Figure 20. Eosinophilic Esophagitis Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 21. Global Eosinophilic Esophagitis Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 22. North America Eosinophilic Esophagitis Drug Sales Market Share by Country (2020-2031)
Figure 23. North America Eosinophilic Esophagitis Drug Revenue Market Share by Country (2020-2031)
Figure 24. U.S. Eosinophilic Esophagitis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 25. Canada Eosinophilic Esophagitis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 26. Europe Eosinophilic Esophagitis Drug Sales Market Share by Country (2020-2031)
Figure 27. Europe Eosinophilic Esophagitis Drug Revenue Market Share by Country (2020-2031)
Figure 28. Germany Eosinophilic Esophagitis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 29. France Eosinophilic Esophagitis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 30. U.K. Eosinophilic Esophagitis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. Italy Eosinophilic Esophagitis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. Russia Eosinophilic Esophagitis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. Asia Pacific Eosinophilic Esophagitis Drug Sales Market Share by Region (2020-2031)
Figure 34. Asia Pacific Eosinophilic Esophagitis Drug Revenue Market Share by Region (2020-2031)
Figure 35. China Eosinophilic Esophagitis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. Japan Eosinophilic Esophagitis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. South Korea Eosinophilic Esophagitis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. India Eosinophilic Esophagitis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. Australia Eosinophilic Esophagitis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. China Taiwan Eosinophilic Esophagitis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. Indonesia Eosinophilic Esophagitis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Thailand Eosinophilic Esophagitis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. Malaysia Eosinophilic Esophagitis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. Philippines Eosinophilic Esophagitis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. Latin America Eosinophilic Esophagitis Drug Sales Market Share by Country (2020-2031)
Figure 46. Latin America Eosinophilic Esophagitis Drug Revenue Market Share by Country (2020-2031)
Figure 47. Mexico Eosinophilic Esophagitis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Brazil Eosinophilic Esophagitis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 49. Argentina Eosinophilic Esophagitis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 50. Middle East and Africa Eosinophilic Esophagitis Drug Sales Market Share by Country (2020-2031)
Figure 51. Middle East and Africa Eosinophilic Esophagitis Drug Revenue Market Share by Country (2020-2031)
Figure 52. Turkey Eosinophilic Esophagitis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 53. Saudi Arabia Eosinophilic Esophagitis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 54. U.A.E Eosinophilic Esophagitis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 55. Global Sales Market Share of Eosinophilic Esophagitis Drug by Type (2020-2031)
Figure 56. Global Revenue Market Share of Eosinophilic Esophagitis Drug by Type (2020-2031)
Figure 57. Global Eosinophilic Esophagitis Drug Price (USD/Unit) by Type (2020-2031)
Figure 58. Global Sales Market Share of Eosinophilic Esophagitis Drug by Application (2020-2031)
Figure 59. Global Revenue Market Share of Eosinophilic Esophagitis Drug by Application (2020-2031)
Figure 60. Global Eosinophilic Esophagitis Drug Price (USD/Unit) by Application (2020-2031)
Figure 61. Eosinophilic Esophagitis Drug Value Chain
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
